Videos

Highlights from the morning session of the C Diff Foundation Conference included data about Pfizer's investigational vaccine, insights about Seres Therapeutics microbiome therapeutic, and a look at CDI incidence rates around COVID-19.

Curtis Donskey, MD, discussed his efforts to encourage C. diff patients and providers to do their part to reduce infection and reinoculation.

The development of these programs are being looked at for private practices in the community settings to try to create better prescribing practices and avoid the potential progression to health care associated infections.

Suzan Walters, PhD, discusses her research on the PrEP care continuum among people who inject drugs in rural versus urban settings.

Loma Linda University worked with local leaders to help promote equitable delivery of COVID-19 vaccines in Black communities.

Booster dose eligibility is broadening as the flu season approaches. An expert emphasizes the need to protect for both COVID-19 and the flu in the coming months.

The company’s current investigational medical device, Sigyn Therapy, is a novel medical device that is being studied for addressing viral pathogens and bacterial toxins to avoid this massive inflammation onslaught and the potential of sepsis.

Merck recently announced results looking at their islatravir implant studied for HIV prevention for 3 months. The long-term goal is to have the implant last 12 months following administration.

Providers offer their insights on this important topic.

A new study shows Medicare-aged patients being treated in hospitals saw more of these types of infections, creating a greater burden on care and costs, and showing an increased mortality rate.

US federal health agencies are recommending an additional shot for this diverse patient population, and here on some insights about vaccine efficacy and breakthrough infections in these groups.

As more agents expand the capability and variety of PrEP options, investigators consider what questions remain about the drug class.

Following the approval of cabotegravir-rilpivirine earlier this year, experts are looking forward to an expansion of the drug class for HIV.

The combination therapy's non-inferior efficacy to heavier TAF regimens may indicate a greater embrace of 2-drug regimens for people living with HIV.

Monica McArthur, MD, PhD, discusses why to-be-authorized COVID-19 vaccine doses for children may not be tiered for patient risk as they were for adults.

New late-breaking data illuminate the specific efficacy of the combination monoclonal antibodies.

A conversation in consideration of the high-risk psychosocial comorbidities the aging HIV population may face through COVID-19.

A new study from IDWeek showed most observed children previously infected with SARS-CoV-2 retained antibodies over 6 months.

An expert reviews cabotegravir, islatravir, lenacapavir, and what other promising agents that could redefine long-term HIV prevention.

A clinician provides an overview of the data on the microbiota-based live biotherapeutic, RBX2660, which in phase 3 studies has shown safety and reduction in recurrent C difficile infection (rCDI).

This type of stewardship is a means of reducing unnecessary testing, getting the appropriate diagnosis more efficiently, and getting patients the appropriate therapy in a timely manner.

The study author of the late-breaking IDWeek findings discusses what the new data mean for using the antiviral to reduce COVID-19 burden.

An expert explains the science of vaccine- and infection-induced immunity, and how it informs the timeline of COVID-19 outbreaks this year.

The Fenway Institute is hosting its upcoming Advancing Excellence in Transgender Health conference. The program will include education on transgender medical care as well as how clinicians and people within this community can interact and the former can understand the latter’s needs when it comes to preventative and acute care.

The emergence of this fungal infection remains mysterious as the world experiences more outbreaks.

With fecal microbiota transplants (FMT) becoming a potential emerging therapy for these patients, here are some aspects to consider when treating.

With the Delta cases surging in recent weeks, and the upcoming flu season almost upon us, here is a glimpse of what providers and the public can expect when both viruses are circulating.

The University of Miami (UM) has a community-based mobile clinic that offers PrEP counseling along with other medical services to those who might not otherwise have access to or seek clinical care.

A study from Mexico shows that maternal mortality increased nearly 60 percent during the COVID-19 pandemic, and reaffirms the importance of both COVID-19 and influenza vaccinations for pregnant women.

With the unpredictability of when it will appear, and its propensity to be multidrug-resistant, this particular pathogen is challenging to diagnose and treat.